Dyspepsia

4
Pipeline Programs
7
Companies
6
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
2
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Takeda
TakedaTOKYO, Japan
1 program
1
Double dose of PPIPhase 41 trial
Active Trials
NCT01888237Completed118Est. Sep 2014
E
EisaiChina - Liaoning
1 program
1
CinitapridePhase 31 trial
Active Trials
NCT01355276Completed400Est. Oct 2011
Novartis
NovartisBASEL, Switzerland
1 program
1
TegaserodPhase 31 trial
Active Trials
NCT00171470Completed60Est. Aug 2006
Ironwood Pharmaceuticals
1 program
1
IW-9179Phase 21 trial
Active Trials
NCT01712412TerminatedEst. Mar 2014
City Therapeutics
City TherapeuticsMA - Cambridge
1 program
MelatoninN/A1 trial
Active Trials
NCT04684199CompletedEst. Apr 2015
Abbott
AbbottABBOTT PARK, IL
1 program
UBT as a Diagnostic Tool for HP PrevalanceN/A1 trial
Active Trials
NCT02570776Unknown200Est. Feb 2016

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
TakedaDouble dose of PPI
EisaiCinitapride
NovartisTegaserod
Ironwood PharmaceuticalsIW-9179
City TherapeuticsMelatonin
AbbottUBT as a Diagnostic Tool for HP Prevalance

Clinical Trials (6)

Total enrollment: 778 patients across 6 trials

NCT01888237TakedaDouble dose of PPI

High Dose PPI Triple Therapy Versus Sequential Therapy for Helicobacter Pylori Eradication

Start: May 2013Est. completion: Sep 2014118 patients
Phase 4Completed
NCT01355276EisaiCinitapride

Efficacy and Safety of Cinitapride Tablets in the Treatment of Mild to Moderate Functional Dyspepsia

Start: Oct 2010Est. completion: Oct 2011400 patients
Phase 3Completed
NCT00171470NovartisTegaserod

The Role of Tegaserod Therapy in the Management of Dyspeptic Symptoms in Female Patients on Proton Pump Inhibitors for the Treatment of Heartburn.

Start: Apr 2005Est. completion: Aug 200660 patients
Phase 3Completed
NCT01712412Ironwood PharmaceuticalsIW-9179

Phase 2a Study of IW-9179 to Treat Functional Dyspepsia

Start: Oct 2012Est. completion: Mar 2014
Phase 2Terminated
NCT04684199City TherapeuticsMelatonin

Melatonin in Pediatric FD Population

Start: Aug 2014Est. completion: Apr 2015
N/ACompleted
NCT02570776AbbottUBT as a Diagnostic Tool for HP Prevalance

UBT as a Diagnostic Tool for HP Prevalance

Start: Dec 2013Est. completion: Feb 2016200 patients
N/AUnknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
7 companies competing in this space